Treatment Optimisation for blood Pressure with Single-Pill Combinations in India (TOPSPIN) study is a multi-center, single-blind trial tailored to South Asian people comparing three Single-Pill Combinations (SPCs) to transform hypertension care. This is a 2-year study by CCDC and funded by Imperial College London, United Kingdom. The study will have a sample size of 1968 patients in total (656 patients per arm). It is currently at the recruitment stage across 35 investigation sites all over India.
Hypertension is a significant cause of mortality and disability in India, affecting around 30% of the population. Importantly, the rates of controlling hypertension are low, standing at 11% in rural areas and 20% in urban areas. Lowering blood pressure to target levels is crucial for preventing cardiovascular issues in hypertensive patients. Often, achieving this goal requires multiple medications. However, there’s a lack of specific trial data on the most effective combinations of antihypertensive drugs for patients of South Asian origin. Current drug selection guidelines in India are primarily based on international standards, which might not fully apply to Indian patients.
In response to this knowledge gap, the TOPSPIN study was designed to compare the effectiveness of three different SPCs of antihypertensive therapies (Amlodipine/Perindopril, Perindopril/Indapamide, and Amlodipine/Indapamide) on 24-hour ambulatory blood pressure levels in Indian patients. This study aims to provide valuable insights for South Asians, who constitute one-sixth of the global population.
